The trajectory of companies tied to Viagra's legacy presents a intricate investment scenario . While the initial boom generated substantial profits , generic copies have significantly eroded sales . Investing in connected pharmaceutical companies now requires a careful assessment of proprietary safeguards, evolving healthcare trends , and the poten